Recent studies indicate that IL-13Rα2 and EGFRvIII expression is significantly heterogeneous in glioma tissues, suggesting that strategies targeting both antigens simultaneously could achieve broader tumor coverage. Here, IL13RA2 is linked to central nervous system cancer.